Patent intelligence · US
US 12226373
Treatment of fragile X syndrome with cannabidiol
Treatment of fragile X syndrome with cannabidiol
Patent details — US 12226373
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 18, 2025
- Expiration
- Feb 13, 2045
- Applicant
- Harmony Biosciences Management, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K31/658, A61K36/185, A61K9/0014
Quick answer
US 12226373 (Treatment of fragile X syndrome with cannabidiol) is held by Harmony Biosciences Management, Inc.. Status: granted. Granted Feb 18, 2025. Expires Feb 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Harmony Biosciences Management, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/658, A61K36/185, A61K9/0014, A61K9/06, A61P
More from Harmony Biosciences Management, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12213951
Treatment of autism with cannabidiol
granted -
US 12186282
Treatment of 22Q11.2 deletion syndrome with cannabidiol
granted -
US 9296774
Halogenated dideoxy sugar derivates, preparation method and application thereof
granted -
US 7625575
Dermatological composition
granted -
US 7582307
Dermatological composition
granted
Frequently asked questions
What is US patent 12226373?
US 12226373 (Treatment of fragile X syndrome with cannabidiol) is held by Harmony Biosciences Management, Inc.. Status: granted. Granted Feb 18, 2025. Expires Feb 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12226373?
Harmony Biosciences Management, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 12226373 expire?
Our index shows an expiration date of Feb 13, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.